MedTrace Logo

Ketamine as an Anaesthetic Agent in Electroconvulsive Therapy (ECT)

NCT00680433 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2013-03-29

No results posted yet for this study

Summary

Research into the mechanisms underlying memory impairment in ECT suggests that its development may be prevented by the administration of certain medications at the time of ECT treatment. For example there are reasons to believe that ketamine, also used as an anaesthetic agent, may have such protective properties.

In this clinical study patients undergoing a course of ECT will be offered the opportunity to receive a small dose of ketamine (or a placebo) as part of their anaesthetic at the time of ECT treatment. Mood changes and any memory changes will be evaluated to see if the subjects who received ketamine had less memory side effects than those who did not, while still improving their depression.

Conditions

  • Major Depressive Episode

Interventions

DRUG

Ketamine

Ketamine IV will be administered after the administration of the normal anaesthetic agents for ECT.

DRUG

Saline

Saline (placebo) will be administered after the normal anaesthetic agents in ECT.

Sponsors & Collaborators

  • Wesley Mission

    collaborator OTHER

  • Northside Clinic, Australia

    lead OTHER

Principal Investigators

  • Colleen K Loo, MB BS FRANZCP, MD · University of New South Wales

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00680433 on ClinicalTrials.gov